Lion Licenses SRS to Incyte | GenomeWeb

NEW YORK, April 2 - Lion Bioscience has licensed its SRS bioinformatics platform to Incyte Genomics for three years, the German company said on Tuesday.

Financial terms of the deal were not disclosed, but Lion said it expects to pocket annual license fees and royalties from Incyte as well as from those Incyte customers that use the SRS-based software platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.